
Health Care · Health Care Supplies
$182.23
+5.01%
Vol: 774K
Thursday, June 18, 2026
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
No material news in the last 48 hours.
At the May 20, 2026 annual meeting, Align Technology shareholders elected all ten director nominees with support of 56.7-59.0M shares each and approved the advisory executive pay plan. Shares climbed 5.3% on the day to $163.42. Earlier in May, the company announced a $200M tranche of buybacks under its $1B repurchase program, running May to October 2026 via a Rule 10b5-1 plan. Q1 2026 results showed record Invisalign shipments of 685.7K units (+6.7% YoY) and revenue of $1.04B (+6.2% YoY). Align was also named a Top 100 Global Innovator in the 2026 LexisNexis Innovation Momentum report for the fifth consecutive year. Analyst consensus is Buy with average price target of $209.07 from 16 analysts.
Align Technology's board authorized a new $1 billion stock repurchase program over three years, with an immediate $200 million Rule 10b5-1 open-market repurchase from May through October 2026. Q1 2026 revenue rose 6.2% YoY to $1.04 billion, beating guidance midpoint by 2%, with adjusted EPS of $2.58 and Clear Aligner revenue up 7.4% to $856M on 6.7% volume growth. Gross margin improved to 70.8%. The company showcased its Invisalign Specifix 3D Printed Attachment System and updated Palatal Expander at the AAO Annual Session May 1-3 in Orlando. Q2 guidance calls for 4% revenue growth. Consensus rating is Buy with median PT of $175.
No material news in the last 48 hours.
Evercore ISI raised its Align Technology price target to $220 from $200 in mid-May 2026 citing margin resilience, while Mizuho Securities reiterated a Buy rating and UBS maintained Hold. The Board authorized a new $1.0 billion stock repurchase program over the next three years, on top of a $200 million plan announced in early May. Q1 2026 revenue grew 6.2% to $1.04 billion with EPS of $1.57, driven by Clear Aligner revenue up 7.4% to $856 million on 6.7% case-shipment growth, with strength in Europe, Asia Pacific and Latin America. Management reaffirmed fiscal 2026 guidance with Q2 revenue growth of approximately 4%. Align was also recognized as a Top 100 Global Innovator for the fifth straight year.
Align Technology reported Q1 2026 revenue of $1.040 billion, up 6.2% year-over-year and 2% above guidance midpoint. Adjusted EPS came in at $2.58, beating FactSet consensus. Clear Aligner revenue rose 7.4% YoY to $856 million driven by double-digit volume growth in Europe, APAC, and Latin America. North America remained stable but lagged. The company launched a $200 million open market stock repurchase on May 1, 2026, to be completed by October 2026. Q2 guidance includes 4% revenue growth driven by sequential aligner growth and flat prices. The stock trades at a premium 29.3x P/E with a recent $153.5M one-off loss limiting room for missteps.
Align Technology reported stronger-than-expected Q1 2026 results on May 13, 2026, with EPS of $2.58 beating forecasts of $2.26 and revenue of $1.04B up 6.2% YoY. Clear Aligner revenue grew 7.4% to $856M as case shipments increased 6.7% to 685.7K. Gross margin improved to 70.8% despite $30.6M of legal settlement expense. The company announced a $200M share repurchase program and reaffirmed fiscal 2026 guidance. ALGN stock traded between $160.88-$165.77 on May 13, with analyst consensus price target of $201.69 indicating significant upside potential. The Q1 beat and capital return should support sentiment, though investors remain focused on macroeconomic pressure on consumer dental spend.
No material news in the last 48 hours.
No material news in the last 48 hours.
Align Technology reported Q1 2026 net revenues of $1,040.1M (+6.2% YoY), with Clear Aligner revenue growing 7.4% to $856M as case shipments rose 6.7% to 685.7 thousand. Net income climbed to $112.8M from $93.2M, with diluted EPS of $1.57 (vs $1.27 prior year). Gross margin improved to 70.8%. The company authorized a $200M share repurchase program beginning around May 1, 2026, and reaffirmed FY 2026 guidance. Strong double-digit volume growth in Europe, Asia Pacific, and Latin America. Zacks upgraded ALGN to Buy. Consensus price target of $201.69. Company showcased innovations at AAO Annual Session May 1-3.
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| WSTWEST | $328.37 | +1.48% | +7.3% | 34.3x | 1.18 | $23.2B |
| ALGNALIGN | $182.23 | +5.01% | +11.4% | 14.7x | 1.67 | $13.0B |
| COOCOOPER | $65.96 | +1.39% | +6.7% | 13.2x | 0.87 | $12.9B |
| LLYELI | $1,099.89 | -1.09% | +7.8% | 24.7x | 0.52 | $979.6B |
| JNJJOHNSON | $228.45 | -2.46% | -0.4% | 18.0x | 0.26 | $549.8B |
Price above both MAs — bullish structure.